CTI in Discussion With U.S. Attorney Regarding TRISENOX(R)
Seattle, November 19 (ots/PRNewswire)
Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; Nuovo Mercato) today announced that it is responding to inquiries from the U.S. Attorney for the Western District of Washington in connection with previously disclosed promotional practices for TRISENOX. CTI is fully cooperating with the U.S. Attorney in this matter.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.cticseattle.com.
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the forward-looking statements contained in this press release include statements about risks and uncertainties that could affect CTI's product TRISENOX(R). These risks include, but are not limited to sales and marketing developments in the biopharmaceutical industry in general and in particular including, without limitation, determinations by regulatory and administrative governmental authorities; and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
Web site: http://www.cticseattle.com
Contact:
investors, Leah Grant, +1-206-282-7100, or fax, +1-206-272-4434, or
invest@ctiseattle.com, or media, Susan Callahan, +1-206-272-4472, or
fax, +1-206-272-4434, or media@ctiseattle.com, both of Cell
Therapeutics, Inc.